| scholarly article | Q13442814 |
| P356 | DOI | 10.1097/CCO.0B013E32832A1868 |
| P698 | PubMed publication ID | 19363343 |
| P2093 | author name string | Nancy A Dawson | |
| Kiran Lassi | |||
| P433 | issue | 3 | |
| P921 | main subject | prostate cancer | Q181257 |
| P304 | page(s) | 260-265 | |
| P577 | publication date | 2009-05-01 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Current Opinion in Oncology | Q1909046 |
| P1476 | title | Emerging therapies in castrate-resistant prostate cancer | |
| P478 | volume | 21 |
| Q33792596 | 'Image and treat': an individualized approach to urological tumors |
| Q39638959 | Adipose tissue-derived mesenchymal stem cells expressing prodrug-converting enzyme inhibit human prostate tumor growth |
| Q39597950 | Amplification and overexpression of vinculin are associated with increased tumour cell proliferation and progression in advanced prostate cancer |
| Q37418731 | Androgen receptor antagonism by divalent ethisterone conjugates in castrate-resistant prostate cancer cells |
| Q53241704 | Antitumor effect of meclofenamic acid on human androgen-independent prostate cancer: a preclinical evaluation. |
| Q51020266 | CIP2A mediates prostate cancer progression via the c-MYC signaling pathway |
| Q38914929 | CIP2A mediates prostate cancer progression via the c-Myc signaling pathway |
| Q37698219 | Cancer vaccine by fusions of dendritic and cancer cells |
| Q35076264 | Castration-resistant prostate cancer: new science and therapeutic prospects |
| Q35111968 | Correlation of Sprouty1 and Jagged1 with aggressive prostate cancer cells with different sensitivities to androgen deprivation |
| Q38030595 | Current and emerging treatments in the management of castration-resistant prostate cancer |
| Q38123202 | Current, new and novel therapy for castration-resistant prostate cancer. |
| Q41520681 | Dendritic cells in cancer immunotherapy: vaccines or autologous transplants? |
| Q39385384 | Design, synthesis, and biological evaluation of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole derivatives as novel androgen receptor antagonists |
| Q38103472 | EZH2, an epigenetic driver of prostate cancer |
| Q33766472 | Efficacy and safety of docetaxel plus prednisolone chemotherapy for metastatic hormone-refractory prostate adenocarcinoma: single institutional study in Korea |
| Q44336766 | Emerging Treatments for Castrate-Resistant Prostate Cancer |
| Q37988590 | Emerging and second line therapies for the management of metastatic castration-resistant prostate cancer: the Australian perspective |
| Q30438965 | Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology |
| Q35163061 | Epigenetic repression of regulator of G‐protein signaling 2 promotes androgen‐independent prostate cancer cell growth |
| Q38728044 | High resolution digital autoradiographic and dosimetric analysis of heterogeneous radioactivity distribution in xenografted prostate tumors |
| Q38532670 | Histological changes caused by meclofenamic acid in androgen-independent prostate cancer tumors: evaluation in a mouse model. |
| Q36125199 | Imaging prostate cancer: an update on positron emission tomography and magnetic resonance imaging |
| Q36243536 | Immunotherapy of cancer in 2012 |
| Q33690450 | Interleukin-6 trans-signalling differentially regulates proliferation, migration, adhesion and maspin expression in human prostate cancer cells |
| Q35053273 | Intratumoral administration of TLR4 agonist absorbed into a cellular vector improves antitumor responses |
| Q39744334 | KLK5 gene expression is severely upregulated in androgen-independent prostate cancer cells after treatment with the chemotherapeutic agents docetaxel and mitoxantrone |
| Q37283578 | Measurement of bone turnover in prostate cancer patients receiving intermittent androgen suppression therapy |
| Q26851177 | Medical strategies for treatment of castration resistant prostate cancer (CRPC) docetaxel resistant |
| Q30500080 | Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistance |
| Q37950459 | Novel therapeutics for the management of castration-resistant prostate cancer (CRPC). |
| Q34667906 | Oncomir miR-125b Suppresses p14ARF to Modulate p53-Dependent and p53-Independent Apoptosis in Prostate Cancer |
| Q36085426 | PET/CT Imaging and Radioimmunotherapy of Prostate Cancer |
| Q39421142 | Pharmacological ascorbate induces cytotoxicity in prostate cancer cells through ATP depletion and induction of autophagy |
| Q37735454 | Polarized dendritic cells as cancer vaccines: directing effector-type T cells to tumors |
| Q36135685 | Prostate specific membrane antigen- a target for imaging and therapy with radionuclides. |
| Q33903836 | Redefining hormone resistance in prostate cancer |
| Q37925129 | Second‐line therapy for castrate‐resistant prostate cancer: A literature review |
| Q35683334 | Serum follicle-stimulating hormone levels predict time to development of castration-resistant prostate cancer |
| Q37760357 | Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy? |
| Q27683734 | Targeting the Binding Function 3 (BF3) Site of the Androgen Receptor Through Virtual Screening. 2. Development of 2-((2-phenoxyethyl) thio)-1H-benzimidazole Derivatives |
| Q27675350 | Targeting the binding function 3 (BF3) site of the human androgen receptor through virtual screening. |
| Q37137452 | Type I Collagen Synthesis Marker Procollagen I N-Terminal Peptide (PINP) in Prostate Cancer Patients Undergoing Intermittent Androgen Suppression |
| Q38262816 | Tyrosine kinase inhibitors in the treatment of prostate cancer: taking the next step in clinical development |
| Q33956051 | Update on options for treatment of metastatic castration-resistant prostate cancer |
| Q39337547 | Zyflamend, a combination of herbal extracts, attenuates tumor growth in murine xenograft models of prostate cancer. |
| Q39649207 | miR‐125b promotes growth of prostate cancer xenograft tumor through targeting pro‐apoptotic genes |
Search more.